7. Discovery and Development of Tenofovir Disoproxil Fumarate

  1. Wieslaw M. Kazmierski
  1. Erik De Clercq

Published Online: 20 JUN 2011

DOI: 10.1002/9780470929353.ch7

Antiviral Drugs: From Basic Discovery through Clinical Trials

Antiviral Drugs: From Basic Discovery through Clinical Trials

How to Cite

De Clercq, E. (2011) Discovery and Development of Tenofovir Disoproxil Fumarate, in Antiviral Drugs: From Basic Discovery through Clinical Trials (ed W. M. Kazmierski), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470929353.ch7

Author Information

  1. Rega Institute for Medical Research, Leuven, Belgium

Publication History

  1. Published Online: 20 JUN 2011
  2. Published Print: 8 AUG 2011

ISBN Information

Print ISBN: 9780470455630

Online ISBN: 9780470929353

SEARCH

Keywords:

  • HIV nucleoside reverse transcriptase inhibitors - tenofovir disoproxil fumarate development;
  • TDF, treatment of hepatitis B - PMEA (adefovir) and PMEDAP, against HBV replication;
  • TDF combined with (–)FTC - better health outcomes at lower costs

Summary

This chapter contains sections titled:

  • Introduction

  • Antiviral Activity Spectrum

  • Mechanism of Anti-HIV Activity and Resistance Development

  • Oral Prodrug Approach: Tenofovir Disoproxil Fumarate

  • Clinical Efficacy of TDF

  • From Viread VIA Truvada to Atripla

  • The Major Pitfall in the Clinical Use of TDF: Kidney Toxicity

  • TDF for the Treatment of Hepatitis B

  • Prophylactic Use of TDF in the Prevention of HIV Infections

  • Conclusions

  • References